Calculation of the optimal structure of antibiotic consumption in a hospital based on the predicted antimicrobial resistance in the treatment of uncomplicated acute pyelonephritis

Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(3):223-231

​ Gomon Yu.M., Arepeva M.A., Kolbin A.S., Kurylyov A.A., Balykina Yu.E., Proskurin M.A., Sidorenko S.V.
10.36488/cmac.2018.3.223-231
antimicrobial resistance mathematic modelling antimicrobials consumption
Section
Antimicrobial Resistance
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(3):223-231

Objective.

To select an optimal (in terms of influence on the antibiotic resistance level) and cost-effective structure of antibiotic consumption in a hospital in the management of patients with acute uncomplicated pyelonephritis.

Materials and Methods.

Based on the literature data as well as a real practice of antibiotic administration, the cost of treatment of an acute uncomplicated pyelonephritis case with different regimens of initial antimicrobial treatment was calculated. Using mathematical modeling, changes in antimicrobial resistance of E. coli taking into consideration the current practice of the antibiotic administration were predicted. The optimal mode of antibiotic consumption in which antimicrobial resistance level would be minimal was predicted.

Results.

The current mode of antibiotic consumption where fluoroquinolones, 3rd generation cephalosporins, and penicillin/beta-lactamase inhibitor combinations account for more than 60% of consumption will lead to an increase in the proportion of extended-spectrum beta-lactamase (ESBL) producing E. coli by 14% over a 5-year period. At the same time, alternative (optimal) mode of antibiotic consumption (i.e. almost complete withdrawal of penicillin/beta-lactamase inhibitor combinations and fluoroquinolones from the clinical practice with the concomitant increase in consumption of carbapenems by 30% and increase in consumption of 3rd generation cephalosporins by 20%) will lead to a decrease in the proportion of ESBLproducing E. coli by 7% over 5 years. The cost of an acute uncomplicated pyelonephritis case with the current mode of antibiotic consumption will be increasing due to an increase in the proportion of ESBLproducing E. coli. At the same time, the alternative (optimal) mode of antibiotic consumption will lead to a significant reduction in the proportion of ESBL-producing E. coli.

Conclusions.

Use of mathematical modeling gives the opportunity to calculate changes in antimicrobial resistance of pathogens and choose the optimal mode of antibiotic consumption to reduce resistance levels.

Yulia M. Gomon

Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia
St. George the Martyr City Hospital, Saint-Petersburg, Russia

Maria A. Arepeva

Saint-Petersburg State University, Saint-Petersburg, Russia

Alexey S. Kolbin

Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia
Saint-Petersburg State University, Saint-Petersburg, Russia

Kurylyov A.A.

Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia

Balykina Yu.E.

Saint-Petersburg State University, Saint-Petersburg, Russia

Proskurin M.A.

Saint-Petersburg State University, Saint-Petersburg, Russia

Sergey V. Sidorenko

Children Scientific Clinical Center of Infectious Diseases, Saint-Petersburg, Russia
North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia

  • 1. Mazhdrakov G., Popov N. Kidney diseases. Sofija: Medicina i fizkul'tura, 1976. 80 p. Russian.
  • 2. Zajcev A.V., Kasjan G.R., Spivak L.G. Acute pyelonephritis in adults. Clinical guidelines, 2016. Available at: http://cr.rosminzdrav.ru. Accessed 25.02.2018. Russian.
  • 3. Rafalsky V.V., Strachunsky L.S., Krechikova O.I., et al. Resistance of hospital urinary infection pathogens by the data of multicenter microbiological studies UTIAP-I and UTIAP-II. Urologija. 2004;2:1317. Russian.
  • 4. Fihn S.D. Clinical practice. Acute uncomplicated urinary tract infection in women. N Engl J Med. 2003;349(3):259-266.
  • 5. Investigation of the dynamics of antibiotic resistance of urinary tract infections causative agents in various subpopulations “DARMIS-2018”. Available at: www.antibiotic.ru/index.php?article=2724. Accessed 01.03.2018. Russian.
  • 6. Palagin I.S., Sukhorukova M.V., Dekhnich A.V., et al. Current State of Antibiotic Resistance of Pathogens Causing CommunityAcquired Urinary Tract Infections in Russia: «DARMIS» Study (20102011). Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2012;4:280-302. Russian.
  • 7. Arepyeva M., Kolbin A., Sidorenko S., et al. A mathematical model for predicting the development of bacterial resistance based on the relationship between the level of antimicrobial resistance and the volume of antibiotic consumption. J Glob Antimicrob Resist. 2017;8:148-156.
  • 8. Arepieva M.A., Kolbin A.S., Sidorenko S.V., et al. Prognostic Model of Microbial Resistance Based on the Relationship between Antibiotic Resistance and Consumption. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2016;18(3):200-211. Russian.
  • 9. European Association of Urology. Guidelines on Urological Infections. Available at: http://uroweb.org/guideline/urologicalinfections/2015. Accessed 01.04.2018.
  • 10. Perepanova T.S., Kozlov R.S., Rudnov V.A., Sinyakova L.A. Antibacterial therapy and prevention of infections of the kidneys, urinary tract and male genital organs. Federal clinical guidelines. M: Prima-print, 72 p. Russian.
  • 11. Kolbin A.S., Zyryanov S.K., Belousov D.Yu., Eds. Basic concepts in assessment of medical technologies: Methodological guidelines. M: Izdatel'stvo OKI, 2013. 42 p. Russian.
  • 12. Sidorenko S.V., Kolbin A.S., Shlyapnikov S.A., et al. Pharmacoepidemiological Study of the Use of Antibacterial Agents in the Multi-Speciality Hospitals of St. Petersburg. Antibiotiki i himioterapija. 2017;62:17-22. Russian.
  • 13. Lee S., Song D.Y., Cho S.H., еt al. Impact of extended-spectrum betalactamase on acute pyelonephritis treated with empirical ceftriaxone. Microb Drug Resist. 2014;20(1):39-44.
  • 14. Suankratay C., Jutivorakool K., Jirajariyavej S. A prospective study of ceftriaxone treatment in acute pyelonephritis caused by extendedspectrum beta-lactamase-producing bacteria. J Med Assoc Thai. 2008;91(8):1172-1181.
  • 15. Tomera K.M., Burdmann E.A., Reyna O.G., et al. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother. 2002;46(9):2895-2900.
  • 16. Shin J., Kim J., Wie S.H., et al. Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact. Microb Drug Resist. 2012;18(2):169-175.
  • 17. Jeon J.H., Kima K., Han W.D., et al. Empirical Use of Ciprofloxacin for Acute Uncomplicated Pyelonephritis Caused by Escherichia coli in Communities Where the Prevalence of Fluoroquinolone Resistance Is High. Antimicrob. Agents Chemother. 2012;56(6):3043-3046.
  • 18. Daneman N., Lu H., Redelmeier D.A. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ. 2015;5:1-9.
  • 19. Arcieri G.M., Becker N., Esposito B., et al. Safety of intravenous ciprofloxacin. A review. Am J Med. 1989;87(5A):92S-97S.
  • 20. Etminan M., Forooghian F., Brophy J.M., et al. Oral fluoroquinolones and the risk of retinal detachment. JAMA. 2012;307(13):1414-1419.
  • 21. Dalgic N., Sancar M., Bayraktar B., et al. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamaseproducing bacteria in children. Scand J Infect Dis. 2011;43(5):339343.
  • 22. Park S.H., Choi S.M., Chang Y.K., et al. The efficacy of noncarbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli. J Antimicrob Chemother. 2014;69(10):2848-2856.
  • 23. Wells W.G., Woods G.L., Jiang Q., et al. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother. 2004;53(Suppl 2):ii67-74.
  • 24. Tomera K.M., Burdmann E.A., Reyna O.G., et al. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother. 2002;46(9):2895-2900.
  • 25. Wie S.H., Kim H.W., Chang U.I. Use of gentamicin for women with community-acquired uncomplicated acute pyelonephritis caused by gentamicin-susceptible or -resistant Escherichia coli: 10-year experience. Microb Drug Resist. 2013;19(4):316-322.
  • 26. Nicolau D.P., Freeman C.D., Belliveau P.P., et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650-655.
  • 27. Territorial fund of compulsory medical insurance of St. Petersburg. General tariff agreement. Available at: https://spboms.ru/page/docs. Accessed 01.04.2018. Russian.
  • 28. Global action plan on antimicrobial resistance. Available at: www.who.int/drugresistance/WHO_Global_Strategy_Russian.pdf. Accessed 01.04.2018. Russian.
  • 29. Arcieri G.M., Becker N., Esposito B., et al. Safety of intravenous ciprofloxacin. A review. Am J Med. 1989;87(5A):92S-97S.
  • 30. Etminan M., Forooghian F., Brophy J.M., et al. Oral fluoroquinolones and the risk of retinal detachment. JAMA. 2012;307(13):1414-1419.
  • 31. U.S. Food and Drug Administration Information for Healthcare Professionals Black Box Warning Fluoroquinolones and Tendinitis and Tendon Rupture. Available at: www.fda.gov/Drugs/DrugSafety/ucm511530.htm (Accessed 01.04.2018).
Views
0 Abstract
0 PDF
0 Crossref citations
Shared